{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T18:13:08Z","timestamp":1789755188481,"version":"4.0.1"},"reference-count":139,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Multiple sclerosis (MS) is primarily an inflammatory and degenerative disease of the central nervous system, triggered by unknown environmental factors in patients with predisposing genetic risk profiles. The prevention of neurological disability is one of the essential goals to be achieved in a patient with MS. However, the pathogenic mechanisms driving the progressive phase of the disease remain unknown. It was described that the pathophysiological mechanisms associated with disease progression are present from disease onset. In daily practice, there is a lack of clinical, radiological, or biological markers that favor an early detection of the disease's progression. Different definitions of disability progression were used in clinical trials. According to the most descriptive, progression was defined as a minimum increase in the Expanded Disability Status Scale (EDSS) of 1.5, 1.0, or 0.5 from a baseline level of 0, 1.0\u20135.0, and 5.5, respectively. Nevertheless, the EDSS is not the most sensitive scale to assess progression, and there is no consensus regarding any specific diagnostic criteria for disability progression. This review document discusses the current pathophysiological concepts associated with MS progression, the different measurement strategies, the biomarkers associated with disability progression, and the available pharmacologic therapeutic approaches.<\/jats:p>","DOI":"10.3389\/fneur.2021.608491","type":"journal-article","created":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T05:51:01Z","timestamp":1617774661000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":35,"title":["Deciphering Multiple Sclerosis Progression"],"prefix":"10.3389","volume":"12","author":[{"given":"Virginia","family":"Meca-Lallana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leticia","family":"Berenguer-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Carreres-Polo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Eichau-Madue\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Ferrer-Lozano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Forero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolanda","family":"Higueras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nieves","family":"T\u00e9llez Lara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Vidal-Jordana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Carlos","family":"P\u00e9rez-Miralles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1093\/brain\/awg081","article-title":"Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process","volume":"126","author":"Confavreux","year":"2003","journal-title":"Brain."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1093\/brain\/awq076","article-title":"Evidence for a two-stage disability progression in multiple sclerosis","volume":"133","author":"Leray","year":"2010","journal-title":"Brain."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1177\/1352458516630396","article-title":"The relationship of age with the clinical phenotype in multiple sclerosis","volume":"22","author":"Scalfari","year":"2016","journal-title":"Mult Scler."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2055217318783347","DOI":"10.1177\/2055217318783347","article-title":"Onset of secondary progressive multiple sclerosis is not influenced by current relapsing multiple sclerosis therapies","volume":"4","author":"Coret","year":"2018","journal-title":"Mult Scler J Exp Transl Clin."},{"key":"B5","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1212\/WNL.46.4.907","article-title":"Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis","volume":"46","author":"Lublin","year":"1996","journal-title":"Neurology."},{"key":"B6","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: The 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology."},{"key":"B7","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ncl.2017.08.006","article-title":"Progressive forms of multiple sclerosis: distinct entity or age-dependent phenomena","volume":"36","author":"Zeydan","year":"2018","journal-title":"Neurol Clin."},{"key":"B8","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1111\/ene.14608","article-title":"The Framingham cardiovascular risk score and 5-year progression of multiple sclerosis","volume":"28","author":"Petruzzo","year":"2021","journal-title":"Eur J Neurol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"102815","DOI":"10.1016\/j.msard.2021.102815","article-title":"Multiple sclerosis and aging: comorbidity and treatment challenges","volume":"50","author":"Ostolaza","year":"2021","journal-title":"Mult Scler Relat Disord."},{"key":"B10","doi-asserted-by":"crossref","DOI":"10.1080\/03007995.2021.1885367","article-title":"Health care resource utilization and disease modifying treatment use in multiple sclerosis patients by age and insurance type","volume-title":"Curr Med Res Opin","author":"Cisternas","year":"2021"},{"key":"B11","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1111\/j.1749-6632.1965.tb20235.x","article-title":"Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis","volume":"122","author":"Schumacker","year":"1965","journal-title":"Ann N Y Acad Sci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/ana.410130302","article-title":"New diagnostic criteria for multiple sclerosis: guidelines for research protocols","volume":"13","author":"Poser","year":"1983","journal-title":"Ann Neurol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/ana.410290111","article-title":"Major differences in the dynamics of primary and secondary progressive multiple sclerosis","volume":"29","author":"Thompson","year":"1991","journal-title":"Ann Neurol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/ana.1032","article-title":"Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis","volume":"50","author":"McDonald","year":"2001","journal-title":"Ann Neurol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1002\/ana.20703","article-title":"Diagnostic criteria for multiple sclerosis: 2005 revisions to the \u201cMcDonald Criteria\u201d","volume":"58","author":"Polman","year":"2005","journal-title":"Ann Neurol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann Neurol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1093\/brain\/awv258","article-title":"Defining reliable disability outcomes in multiple sclerosis","volume":"138","author":"Kalincik","year":"2015","journal-title":"Brain."},{"key":"B19","doi-asserted-by":"publisher","first-page":"a028936","DOI":"10.1101\/cshperspect.a028936","article-title":"Multiple Sclerosis Pathology","volume":"8","author":"Lassmann","year":"2018","journal-title":"Cold Spring Harb Perspect Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1093\/brain\/awv398","article-title":"The topograpy of demyelination and neurodegeneration in the multiple sclerosis brain Brain Advance Access","volume":"139","author":"Haider","year":"2016","journal-title":"Brain."},{"key":"B21","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q","article-title":"Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination","volume":"47","author":"Lucchinetti","year":"2000","journal-title":"Ann Neurol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1002\/ana.24163","article-title":"Pathologic heterogeneity persists in early active multiple sclerosis lesions","volume":"75","author":"Metz","year":"2014","journal-title":"Ann Neurol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/ana.20016","article-title":"Relapsing and remitting multiple sclerosis: Pathology of the newly forming lesion","volume":"55","author":"Barnett","year":"2004","journal-title":"Ann Neurol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/ana.21311","article-title":"Homogeneity of active demyelinating lesions in established multiple sclerosis","volume":"63","author":"Breij","year":"2008","journal-title":"Ann Neurol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1093\/brain\/awh641","article-title":"Cortical demyelination and diffuse white matter injury in multiple sclerosis","volume":"128","author":"Kutzelnigg","year":"2005","journal-title":"Brain."},{"key":"B26","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/ana.1123","article-title":"Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions","volume":"50","author":"Peterson","year":"2001","journal-title":"Ann Neurol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1093\/brain\/awt110","article-title":"Disease-specific molecular events in cortical multiple sclerosis lesions","volume":"136","author":"Fischer","year":"2013","journal-title":"Brain."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1093\/brain\/awn105","article-title":"Mitochondrial defects in acute multiple sclerosis lesions","volume":"131","author":"Mahad","year":"2008","journal-title":"Brain."},{"key":"B29","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/S1474-4422(09)70043-2","article-title":"Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis","volume":"8","author":"Trapp","year":"2009","journal-title":"Lancet Neurol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/nrneurol.2012.168","article-title":"Progressive multiple sclerosis: pathology and pathogenesis","volume":"8","author":"Lassmann","year":"2012","journal-title":"Nat Rev Neurol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology."},{"key":"B32","unstructured":"Clinical Investigation of Medicinal Products for the Treatment of Multiple Sclerosis2015"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1093\/brain\/aww173","article-title":"Defining secondary progressive multiple sclerosis","volume":"139","author":"Lorscheider","year":"2016","journal-title":"Brain."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1212\/WNL.46.6.1613","article-title":"Meta-analysis of the placebo-treated groups in clinical trials of progressive MS","volume":"46","author":"Weinshenker","year":"1996","journal-title":"Neurology."},{"key":"B35","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1212\/WNL.0b013e3181ecf815","article-title":"Measuring disability in relapsing-remitting MS","volume":"75","author":"Rudick","year":"2010","journal-title":"Neurology."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1093\/brain\/awq058","article-title":"Resting state networks change in clinically isolated syndrome","volume":"133","author":"Roosendaal","year":"2010","journal-title":"Brain."},{"key":"B37","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1212\/WNL.0000000000001094","article-title":"Relapses and disability accumulation in progressive multiple sclerosis","volume":"84","author":"Paz Soldan","year":"2015","journal-title":"Neurology."},{"key":"B38","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1002\/ana.25463","article-title":"Silent progression in disease activity-free relapsing multiple sclerosis","volume":"85","author":"Cree","year":"2019","journal-title":"Ann Neurol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1002\/ana.25537","article-title":"Silent progression or bout onset progressive multiple sclerosis?","volume":"86","author":"Gil-Perotin","year":"2019","journal-title":"Ann Neurol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1212\/01.wnl.0000313034.46883.16","article-title":"Disability as an outcome in MS clinical trials","volume":"71","author":"Ebers","year":"2008","journal-title":"Neurology."},{"key":"B41","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.jns.2006.06.031","article-title":"Clinical outcome measures in multiple sclerosis","volume":"259","author":"Amato","year":"2007","journal-title":"J Neurol Sci."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1177\/1352458511433919","article-title":"Temporal evolution of remission following multiple sclerosis relapse and predictors of outcome","volume":"18","author":"Hirst","year":"2012","journal-title":"Mult Scler."},{"key":"B43","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1177\/1352458517709619","article-title":"Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study","volume":"24","author":"Kappos","year":"2018","journal-title":"Mult Scler."},{"key":"B44","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/0165-5728(95)98993-L","article-title":"Is it possible to achieve cross-cultural european agreement in the assessment of neurological deficits? First experiences in the european interferon-beta 1B trial for secondary progressive MS","author":"Lechner-Scott","year":"1995","journal-title":"J Neuroimmunol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1093\/brain\/122.5.871","article-title":"Development of a multiple sclerosis functional composite as a clinical trial outcome measure","volume":"122","author":"Cutter","year":"1999","journal-title":"Brain."},{"key":"B46","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/S1474-4422(14)70264-9","article-title":"Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives","volume":"14","author":"Ontaneda","year":"2015","journal-title":"Lancet Neurol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1177\/1352458510370464","article-title":"Progression on the multiple sclerosis functional composite in multiple sclerosis: what is the optimal cut-off for the three components?","volume":"16","author":"Bosma","year":"2010","journal-title":"Mult Scler."},{"key":"B48","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1001\/archneur.59.1.113","article-title":"A study validating changes in the multiple sclerosis functional composite","volume":"59","author":"Hoogervorst","year":"2002","journal-title":"Arch Neurol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1177\/1352458516638941","article-title":"The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis","volume":"23","author":"Cadavid","year":"2017","journal-title":"Mult Scler."},{"key":"B50","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1002\/ana.25313","article-title":"Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial","volume":"84","author":"Wolinsky","year":"2018","journal-title":"Ann Neurol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1177\/1352458517690823","article-title":"Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis","volume":"23","author":"Motl","year":"2017","journal-title":"Mult Scler."},{"key":"B52","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1177\/1352458517690824","article-title":"The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis","volume":"23","author":"Feys","year":"2017","journal-title":"Mult Scler."},{"key":"B53","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1177\/1352458517690822","article-title":"Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis","volume":"23","author":"Balcer","year":"2017","journal-title":"Mult Scler."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1007\/s00415-015-7764-x","article-title":"Walking function in clinical monitoring of multiple sclerosis by telemedicine","volume":"262","author":"Sola-Valls","year":"2015","journal-title":"J Neurol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"e190570","DOI":"10.1001\/jamanetworkopen.2019.0570","article-title":"Association of Continuous Assessment Of Step Count By Remote Monitoring With Disability Progression Among Adults With Multiple Sclerosis","volume":"2","author":"Block","year":"2019","journal-title":"JAMA Netw Open."},{"key":"B56","doi-asserted-by":"publisher","first-page":"c186","DOI":"10.1136\/bmj.c186","article-title":"The routine use of patient reported outcome measures in healthcare settings","volume":"340","author":"Dawson","year":"2010","journal-title":"BMJ."},{"key":"B57","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/ene.13786","article-title":"Patient-reported outcomes are worse for progressive-onset multiple sclerosis than relapse-onset multiple sclerosis, particularly early in the disease process","volume":"26","author":"Zhang","year":"2019","journal-title":"Eur J Neurol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1111\/ene.13339","article-title":"Patient-reported outcomes in multiple sclerosis: a systematic comparison of available measures","volume":"24","author":"Khurana","year":"2017","journal-title":"Eur J Neurol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1136\/bmj.306.6890.1437","article-title":"Short form 36 (SF36) health survey questionnaire: normative data for adults of working age","volume":"306","author":"Jenkinson","year":"1993","journal-title":"BMJ."},{"key":"B60","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s10198-019-01068-9","article-title":"EQ-5D studies in nervous system diseases in eight Central and East European countries: a systematic literature review","volume":"20","author":"Prevolnik Rupel","year":"2019","journal-title":"Eur J Heal Econ."},{"key":"B61","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1177\/1352458507080733","article-title":"Validation of the multiple sclerosis international quality of life questionnaire","volume":"14","author":"Simeoni","year":"2008","journal-title":"Mult Scler."},{"key":"B62","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1093\/brain\/124.5.962","article-title":"The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure","volume":"124","author":"Hobart","year":"2001","journal-title":"Brain."},{"key":"B63","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1212\/WNL.60.1.31","article-title":"Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12)","volume":"60","author":"Hobart","year":"2003","journal-title":"Neurology."},{"key":"B64","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1191\/1352458505ms1117oa","article-title":"Evaluation of the modified fatigue impact scale in four different European countries","volume":"11","author":"Kos","year":"2005","journal-title":"Mult Scler."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1177\/1352458518803785","article-title":"Recommendations for cognitive screening and management in multiple sclerosis care","volume":"24","author":"Kalb","year":"2018","journal-title":"Mult Scler."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1007\/s10072-018-3427-x","article-title":"Cognitive assessment in multiple sclerosis-an Italian consensus","volume":"39","author":"Amato","year":"2018","journal-title":"Neurol Sci."},{"key":"B67","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/14737175.2019.1590199","article-title":"Identifying risk factors for cognitive issues in multiple sclerosis","volume":"19","author":"Amato","year":"2019","journal-title":"Expert Rev Neurother."},{"key":"B68","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1111\/ene.13904","article-title":"Predicting clinical progression in multiple sclerosis after 6 and 12 years","volume":"26","author":"Dekker","year":"2019","journal-title":"Eur J Neurol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/ene.12715","article-title":"Cognitive impairment in a population-based study of patients with multiple sclerosis: differences between late relapsing-remitting, secondary progressive and primary progressive multiple sclerosis","volume":"23","author":"Planche","year":"2016","journal-title":"Eur J Neurol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1212\/WNL.0000000000004977","article-title":"Cognition in multiple sclerosis: State of the field and priorities for the future","volume":"90","author":"Sumowski","year":"2018","journal-title":"Neurology."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1080\/13854046.2010.511272","article-title":"Predicting loss of employment over three years in multiple sclerosis: clinically meaningful cognitive decline","volume":"24","author":"Morrow","year":"2010","journal-title":"Clin Neuropsychol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1177\/1352458515599075","article-title":"Cognitive impairment at diagnosis predicts 10-year multiple sclerosis progression","volume":"22","author":"Moccia","year":"2016","journal-title":"Mult Scler."},{"key":"B73","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1177\/1352458510362819","article-title":"Early cognitive impairment in multiple sclerosis predicts disability outcome several years later","volume":"16","author":"Deloire","year":"2010","journal-title":"Mult Scler."},{"key":"B74","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1017\/S135561770809005X","article-title":"Negative affect predicts subsequent cognitive change in multiple sclerosis","volume":"15","author":"Christodoulou","year":"2009","journal-title":"J Int Neuropsychol Soc."},{"key":"B75","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1111\/j.1468-1331.2008.02241.x","article-title":"Natural history of multiple sclerosis in a population-based cohort","volume":"15","author":"Debouverie","year":"2008","journal-title":"Eur J Neurol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1136\/jnnp-2013-307275","article-title":"Isolated cognitive relapses in multiple sclerosis","volume":"85","author":"Pardini","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B77","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1097\/WCO.0000000000000572","article-title":"MRI in multiple sclerosis: what is changing?","volume":"31","author":"Filippi","year":"2018","journal-title":"Curr Opin Neurol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s40120-018-0103-2","article-title":"Monitoring progressive multiple sclerosis with novel imaging techniques","volume":"7","author":"Petracca","year":"2018","journal-title":"Neurol Ther."},{"key":"B79","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s11940-018-0496-3","article-title":"Disease-modifying treatment in progressive multiple sclerosis","volume":"20","author":"Ciotti","year":"2018","journal-title":"Curr Treat Options Neurol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1093\/brain\/awv105","article-title":"Defining high, medium and low impact prognostic factors for developing multiple sclerosis","volume":"138","author":"Tintore","year":"2015","journal-title":"Brain."},{"key":"B81","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nrneurol.2015.157","article-title":"MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-establishing disease prognosis and monitoring patients","volume":"11","author":"Wattjes","year":"2015","journal-title":"Nat Rev Neurol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1093\/brain\/awz156","article-title":"Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis","volume":"142","author":"Brownlee","year":"2019","journal-title":"Brain."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1177\/1352458518814117","article-title":"Slowly expanding\/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions","volume":"25","author":"Elliott","year":"2019","journal-title":"Mult Scler."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1756286419859722","DOI":"10.1177\/1756286419859722","article-title":"Advances in brain imaging in multiple sclerosis","volume":"12","author":"Cortese","year":"2019","journal-title":"Ther Adv Neurol Disord."},{"key":"B85","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1177\/1756285617708911","article-title":"MRI in the assessment and monitoring of multiple sclerosis: an update on best practice","volume":"10","author":"Kaunzner","year":"2017","journal-title":"Ther Adv Neurol Disord."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1001\/jamaneurol.2019.2399","article-title":"Association of chronic active multiple sclerosis lesions with disability in vivo","volume":"76","author":"Absinta","year":"2019","journal-title":"JAMA Neurol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1002\/ana.21906","article-title":"A 3-year magnetic resonance imaging study of cortical lesions in relapse-onset multiple sclerosis","volume":"67","author":"Calabrese","year":"2010","journal-title":"Ann Neurol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1093\/brain\/aws246","article-title":"Cortical lesion load associates with progression of disability in multiple sclerosis","volume":"135","author":"Calabrese","year":"2012","journal-title":"Brain."},{"key":"B89","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1177\/1352458515604905","article-title":"Grey matter involvement by focal cervical spinal cord lesions is associated with progressive multiple sclerosis","volume":"22","author":"Kearney","year":"2016","journal-title":"Mult Scler."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.3174\/ajnr.A5796","article-title":"Longitudinal persistence of meningeal enhancement on postcontrast 7T 3D-FLAIR MRI in multiple sclerosis","volume":"39","author":"Jonas","year":"2018","journal-title":"AJNR Am J Neuroradiol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/j.ejrad.2015.05.004","article-title":"MRI detection of hypointense brain lesions in patients with multiple sclerosis: T1 spin-echo vs. gradient-echo","volume":"84","author":"Dupuy","year":"2015","journal-title":"Eur J Radiol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1093\/brain\/awv337","article-title":"Cortical atrophy patterns in multiple sclerosis are non-random and clinically relevant","volume":"139","author":"Steenwijk","year":"2015","journal-title":"Brain."},{"key":"B93","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.nic.2017.01.002","article-title":"Brain atrophy in multiple sclerosis: clinical relevance and technical aspects","volume":"27","author":"Sastre-Garriga","year":"2017","journal-title":"Neuroimaging Clin N Am."},{"key":"B94","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1111\/jon.12553","article-title":"Spinal cord atrophy in multiple sclerosis: a systematic review and meta-analysis","volume":"28","author":"Casserly","year":"2018","journal-title":"J Neuroimaging."},{"key":"B95","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1136\/jnnp-2014-308021","article-title":"Cervical spinal cord volume loss is related to clinical disability progression in multiple sclerosis","volume":"86","author":"Lukas","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B96","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s00415-011-6195-6","article-title":"The role of advanced magnetic resonance imaging techniques in primary progressive MS","volume":"259","author":"Rocca","year":"2012","journal-title":"J Neurol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"553","DOI":"10.33588\/rn.5812.2014247","article-title":"Biomarkers in multiple sclerosis: an update for 2014","volume":"58","author":"Fernandez","year":"2014","journal-title":"Rev Neurol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"46S","DOI":"10.1177\/1051228405284200","article-title":"Magnetic resonance spectroscopy in the monitoring of multiple sclerosis","volume":"15","author":"Narayana","year":"2005","journal-title":"J Neuroimaging."},{"key":"B99","doi-asserted-by":"publisher","first-page":"942","DOI":"10.3174\/ajnr.A5109","article-title":"Cognitive implications of deep gray matter iron in multiple sclerosis","volume":"38","author":"Fujiwara","year":"2017","journal-title":"AJNR Am J Neuroradiol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1148\/radiol.12120707","article-title":"Quantitative susceptibility mapping in multiple sclerosis","volume":"267","author":"Langkammer","year":"2013","journal-title":"Radiology."},{"key":"B101","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S0733-8619(18)31028-4","article-title":"Electrophysiologic evaluation of patients with multiple sclerosis","volume":"3","author":"Aminoff","year":"1985","journal-title":"Neurol Clin."},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-09964-4","article-title":"Early diagnosis of secondary progressive multiple sclerosis: focus on fluid and neurophysiological biomarkers","author":"Ferrazzano","year":"2020","journal-title":"J Neurol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S1474-4422(13)70233-3","article-title":"Body fluid biomarkers in multiple sclerosis","volume":"13","author":"Comabella","year":"2014","journal-title":"Lancet Neurol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1001\/jamaneurol.2019.0905","article-title":"Association of intrathecal immunoglobulin g synthesis with disability worsening in multiple sclerosis","volume":"76","author":"Gasperi","year":"2019","journal-title":"JAMA Neurol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1177\/1352458510389102","article-title":"Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course","volume":"17","author":"Khademi","year":"2011","journal-title":"Mult Scler."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1093\/brain\/awf165","article-title":"Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations","volume":"125","author":"Petzold","year":"2002","journal-title":"Brain."},{"key":"B107","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1007\/s00415-010-5863-2","article-title":"Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis","volume":"258","author":"Axelsson","year":"2011","journal-title":"J Neurol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1177\/1352458514549397","article-title":"Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis","volume":"21","author":"Mart\u00ednez","year":"2015","journal-title":"Mult Scler."},{"key":"B109","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1177\/1352458509359725","article-title":"Neurofilament light as a prognostic marker in multiple sclerosis","volume":"16","author":"Salzer","year":"2010","journal-title":"Mult Scler."},{"key":"B110","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1001\/jamaneurol.2019.2137","article-title":"Association between serum neurofilament light chain levels and long-term disease course among patients with multiple sclerosis followed up for 12 years","volume":"76","author":"Cant\u00f3","year":"2019","journal-title":"JAMA Neurol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"e815","DOI":"10.1212\/NXI.0000000000000815","article-title":"CSF chitinase 3-like-1 association with disability of primary progressive MS","volume":"7","author":"P\u00e9rez-Miralles","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B112","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1093\/brain\/awy154","article-title":"Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis","volume":"141","author":"Barro","year":"2018","journal-title":"Brain."},{"key":"B113","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/ana.24954","article-title":"Serum Neurofilament light: a biomarker of neuronal damage in multiple sclerosis","volume":"81","author":"Disanto","year":"2017","journal-title":"Ann Neurol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1136\/jnnp-2018-319190","article-title":"Cerebrospinal fluid neurofilament light chain in multiple sclerosis and its subtypes: a meta-analysis of case-control studies","volume":"90","author":"Martin","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B115","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/S1474-4422(10)70168-X","article-title":"Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis","volume":"9","author":"Petzold","year":"2010","journal-title":"Lancet Neurol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S1474-4422(17)30278-8","article-title":"Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis","volume":"16","author":"Petzold","year":"2017","journal-title":"Lancet Neurol."},{"key":"B117","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/S1474-4422(16)00068-5","article-title":"Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study","volume":"15","author":"Martinez-Lapiscina","year":"2016","journal-title":"Lancet Neurol."},{"key":"B118","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1177\/1352458517740216","article-title":"Peripapillary retinal nerve fibre layer as measured by optical coherence tomography is a prognostic biomarker not only for physical but also for cognitive disability progression in multiple sclerosis","volume":"25","author":"Bsteh","year":"2019","journal-title":"Mult Scler."},{"key":"B119","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1007\/s40265-018-0984-5","article-title":"Therapeutic advances and challenges in the treatment of progressive multiple sclerosis","volume":"78","author":"Baldassari","year":"2018","journal-title":"Drugs."},{"key":"B120","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1093\/brain\/aww258","article-title":"Progressive multiple sclerosis: from pathogenic mechanisms to treatment","volume":"140","author":"Correale","year":"2017","journal-title":"Brain."},{"key":"B121","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1177\/1352458517729455","article-title":"Targets of therapy in progressive MS","volume":"23","author":"Lassmann","year":"2017","journal-title":"Mult Scler."},{"key":"B122","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","article-title":"Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study","volume":"391","author":"Kappos","year":"2018","journal-title":"Lancet."},{"key":"B123","doi-asserted-by":"publisher","first-page":"e66308","DOI":"10.1371\/journal.pone.0066308","article-title":"Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review","volume":"8","author":"Castillo-Trivino","year":"2013","journal-title":"PLoS One."},{"key":"B124","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/ana.21867","article-title":"Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial","volume":"66","author":"Hawker","year":"2009","journal-title":"Ann Neurol."},{"key":"B125","unstructured":"EPAR IFN beta 1b sc"},{"key":"B126","unstructured":"EPAR IFN beta 1a sc"},{"key":"B127","unstructured":"EPAR Mitoxantrone"},{"key":"B128","unstructured":"EPAR Ocrelizumab"},{"key":"B129","unstructured":"EPAR Siponimod"},{"key":"B130","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1136\/jnnp-2012-303291","article-title":"Interferon \u03b2 for secondary progressive multiple sclerosis: a systematic review","volume":"84","author":"La Mantia","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B131","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1212\/WNL.60.1.44","article-title":"Interferon \u03b2-1a in primary progressive MS: an exploratory, randomized, controlled trial","volume":"60","author":"Leary","year":"2003","journal-title":"Neurology."},{"key":"B132","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1177\/1352458509106937","article-title":"A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis","volume":"15","author":"Montalban","year":"2009","journal-title":"Mult Scler."},{"key":"B133","doi-asserted-by":"publisher","first-page":"e0138243","DOI":"10.1371\/journal.pone.0138243","article-title":"Evaluation of study and patient characteristics of clinical studies in primary progressive multiple sclerosis: A systematic review","volume":"10","author":"Ziemssen","year":"2015","journal-title":"PLoS ONE."},{"key":"B134","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/S0140-6736(15)01314-8","article-title":"Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"387","author":"Lublin","year":"2016","journal-title":"Lancet."},{"key":"B135","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1177\/1352458517729460","article-title":"Progressive MS trials: lessons learned","volume":"23","author":"Tur","year":"2017","journal-title":"Mult Scler."},{"key":"B136","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S1474-4422(18)30069-3","article-title":"Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension","volume":"17","author":"Kapoor","year":"2018","journal-title":"Lancet Neurol."},{"key":"B137","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N Engl J Med."},{"key":"B138","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/S1474-4422(20)30342-2","article-title":"Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial","volume":"19","author":"Wolinsky","year":"2020","journal-title":"Lancet Neurol."},{"key":"B139","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","article-title":"Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the guideline development, dissemination, and implementation subcommittee of the american academy of neurology","volume":"90","author":"Rae-Grant","year":"2018","journal-title":"Neurology."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.608491\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T15:56:14Z","timestamp":1671810974000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.608491\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,7]]},"references-count":139,"alternative-id":["10.3389\/fneur.2021.608491"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.608491","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,7]]},"article-number":"608491"}}